Uses of Sagafosa

Sagafosa medicine has the main ingredient is Sodium Alendronate, used in the treatment of some bone and joint diseases. The drug should be used according to the doctor's prescription and instructions. Let's learn about the use of Sagafosa through the following sharing!

Sagafosa contains the main active ingredient, Sodium Alendronate. Alendronate is an Amino bisphosphonate with specific inhibitory effects on bone resorption. Several preclinical studies have shown that alendronate selectively accumulates at sites of active bone resorption. Clinical studies have shown that preclinical treatment with the active ingredient alendronate can significantly increase bone mass in the femoral neck and spine or trochanter.

2.1 Indications for use of the drug Sagafosa Sagafosa is used in the treatment of a number of diseases such as:
Osteoporosis: Treatment and prevention of osteoporosis in postmenopausal women. Treatment of osteoporosis in men. Treatment of osteoporosis caused by long-term use of corticosteroids. Paget's disease occurs in the bones (also known as deforming osteomyelitis). 2.2 Contraindications to the use of the drug Sagafosa Sagafosa is contraindicated in some cases:
Abnormalities in the esophagus that delay esophageal emptying such as esophageal stricture or nondilation. The patient cannot stand or sit upright for at least 30 minutes. Patients with hypersensitivity to any of the ingredients in the drug. Low blood calcium.

Like other bisphosphonate drugs, Alendronate can cause some symptoms and side effects in the gastrointestinal tract such as: Constipation, diarrhea, abdominal pain or indigestion.
Some symptoms such as dysphagia, heartburn, painful swallowing or pain below the sternum require appropriate care.
Patients should immediately notify the doctor when severe symptoms appear in the esophagus such as: esophageal stricture and ulceration, esophagitis, erosion, ...

How to take Sagafosa:
Alendronat is used orally. Patients do not suck or chew, only take the drug in the early morning, with a full glass of water (about 250ml) at least 30 minutes before eating. Can drink or use Sagafosa with 1 other medicine during the day. Dosage of Sagafosa:
Treatment of osteoporosis:
Treatment of osteoporosis in postmenopausal women: 10 mg/day or 70mg/time/week. Prevention of osteoporosis in postmenopausal women: 5mg/day or 35mg/time/week. Treatment of osteoporosis for men: 10mg/day or 70mg/time/week. Treatment of osteoporosis caused by long-term use of anti-inflammatory corticosteroids: 5 mg/day. Postmenopausal women not taking hormone replacement therapy should take 10mg/day. Paget's disease in bone: Adults use 40mg / time / day for 6 months. Repeat treatment if necessary after more than 6 months of treatment.

Overdose symptoms:
Overdosage of Sagafosa can cause hypocalcemia, hypophosphataemia and side effects in the upper gastrointestinal tract such as: esophagitis, stomach pain, heartburn, gastritis, or ulcers. may be caused by an overdose. Instructions for treatment of overdose:
Currently, there is no specific treatment for overdosage of Sagafosa. Therefore, milk or antacids can be taken to bind Alendronate. The patient should be kept upright because the risk of esophageal irritation and vomiting is not reduced.

Intravenous ranitidine may double the oral bioavailability of Sagafosa. In healthy subjects, oral administration of prednisone (20 mg 3 times/day x 5 days) did not cause clinically significant changes in the oral bioavailability of alendronate (a significant increase was varies from 20 to 44%). Non-steroidal anti-inflammatory drugs (NSAIDs): Co-administration with Alendronate may increase the risk of gastric ulceration, so the combination should be used with caution. Iron: Oral iron drugs reduce absorption of Alendronate Aminoglycoside antibiotics: Increased risk of hypocalcemia if used concomitantly with Alendronate. Milk, calcium supplements, magnesium or aluminum-containing drugs (antacids): May reduce absorption of Alendronate. Therefore, patients must wait at least 30 minutes after taking Alendronate before taking any other medicine. To avoid interactions, before being prescribed Sagafosa, patients should inform their doctors about all the drugs they are using, including functional foods. The doctor will base on that to prescribe the appropriate Sagafosa.

Sagafosa should not be used in patients with esophageal abnormalities or other factors that may delay esophageal emptying, who cannot stand or sit upright for at least 30 minutes. Sagafosa should be used with caution in patients with upper gastrointestinal tract abnormalities. To reduce the risk of esophageal reactions:
Patients should take Sagafosa tablets with plenty of water (not less than 200 ml), kept in an upright position (standing or sitting). Avoid drinking mineral water with high calcium concentration. Sagafosa should be taken early in the morning, on an empty stomach, at least 30 minutes before breakfast and other drugs. The patient should be kept upright after taking the drug and should not lie down before the first meal of the day. Sagafosa should not be taken at bedtime, or before getting up for the day. Before starting Sagafosa, it is recommended to treat hypocalcaemia, as well as other disorders affecting mineral metabolism such as vitamin D deficiency or hypoparathyroidism; Serum calcium for these subjects should be monitored during treatment. For pregnant women, use during pregnancy only when the potential benefit outweighs the potential risk to the mother and fetus. Caution should be exercised when administering Sagafosa to a nursing woman. Above is all information about Sagafosa drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Sagafosa medicine at home because there may be unwanted side effects.